Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 676198, 11 pages
http://dx.doi.org/10.1155/2011/676198
Review Article

Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications

1Centro de Investigaciones Oncológicas, Fundación Cáncer e Instituto Alexander Fleming, Cramer 1180, Ciudad Autónoma de Buenos Aires C1426ANZ, Argentina
2IIBBA-CONICET, Fundación Instituto Leloir, Avendia Patricias Argentinas 435, Ciudad Autónoma de Buenos Aires C1405BWE, Argentina

Received 29 December 2010; Accepted 25 February 2011

Academic Editor: Roberto Biassoni

Copyright © 2011 Estrella Mariel Levy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of natural killer cells,” Nature Immunology, vol. 9, no. 5, pp. 503–510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Trinchieri, “Biology of natural killer cells,” Advances in Immunology, vol. 47, pp. 187–376, 1989. View at Google Scholar · View at Scopus
  3. S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama, “In vivo natural killer cell activities revealed by natural killer cell-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2731–2736, 2000. View at Google Scholar · View at Scopus
  4. M. J. Smyth, Y. Hayakawa, K. Takeda, and H. Yagita, “New aspects of natural-killer-cell surveillance and therapy of cancer,” Nature Reviews Cancer, vol. 2, no. 11, pp. 850–861, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Wu and L. L. Lanier, “Natural killer cells and cancer,” Advances in Cancer Research, vol. 90, pp. 127–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. A. Stewart and E. Vivier, “Strategies of NK cell recognition and their roles in tumor immunosurveillance,” in How the Immune System Recognizes Self and Nonself: Immunoreceptors and Their Signaling, D. Kitamura, Ed., pp. 37–81, Springer, Tokyo, Japan, 2007. View at Google Scholar
  7. D. H. Kaplan, V. Shankaran, A. S. Dighe et al., “Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7556–7561, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Shankaran, H. Ikeda, A. T. Bruce et al., “IFNγ, and lymphocytes prevent primary tumour development and shape tumour immunogenicity,” Nature, vol. 410, no. 6832, pp. 1107–1111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. C. M. Koebel, W. Vermi, J. B. Swann et al., “Adaptive immunity maintains occult cancer in an equilibrium state,” Nature, vol. 450, no. 7171, pp. 903–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Karre, H. G. Ljunggren, G. Piontek, and R. Kiessling, “Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy,” Nature, vol. 319, no. 6055, pp. 675–678, 1986. View at Google Scholar · View at Scopus
  11. A. Diefenbach, E. R. Jensen, A. M. Jamieson, and D. H. Raulet, “Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity,” Nature, vol. 413, no. 6852, pp. 165–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Cerwenka, J. L. Baron, and L. L. Lanier, “Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11521–11526, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Kelly, P. K. Darcy, J. L. Markby et al., “Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection,” Nature Immunology, vol. 3, no. 1, pp. 83–90, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Sun and L. L. Lanier, “Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity?” European Journal of Immunology, vol. 39, no. 8, pp. 2059–2064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. E. A. Street, Y. Hayakawa, Y. Zhan et al., “Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells,” Journal of Experimental Medicine, vol. 199, no. 6, pp. 879–884, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Y. Koh, B. R. Blazar, T. George et al., “Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo,” Blood, vol. 97, no. 10, pp. 3132–3137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. Orange, “Human natural killer cell deficiencies,” Current Opinion in Allergy and Clinical Immunology, vol. 6, no. 6, pp. 399–409, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Imai, S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi, “Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population,” The Lancet, vol. 356, no. 9244, pp. 1795–1799, 2000. View at Google Scholar · View at Scopus
  19. S. Coca, J. Perez-Piqueras, D. Martinez et al., “The prognostic significance of intratumoral natural killer cells in patients with colerectal carcinoma,” Cancer, vol. 79, no. 12, pp. 2320–2328, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ishigami, S. Natsugoe, K. Tokuda et al., “Prognostic value of intratumoral natural killer cells in gastric carcinoma,” Cancer, vol. 88, no. 3, pp. 577–583, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. F. R. Villegas, S. Coca, V. G. Villarrubia et al., “Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer,” Lung Cancer, vol. 35, no. 1, pp. 23–28, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. P. A. Albertsson, P. H. Basse, M. Hokland et al., “NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity,” Trends in Immunology, vol. 24, no. 11, pp. 603–609, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Esendagli, K. Bruderek, T. Goldmann et al., “Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer,” Lung Cancer, vol. 59, no. 1, pp. 32–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Hokland, J. Kjaergaard, P. J. K. Kuppen et al., “Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation,” In Vivo, vol. 13, no. 3, pp. 199–204, 1999. View at Google Scholar · View at Scopus
  25. K. C. Hsu, C. A. Keever-Taylor, A. Wilton et al., “Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes,” Blood, vol. 105, no. 12, pp. 4878–4884, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Ruggeri, A. Mancusi, E. Burchielli, F. Aversa, M. F. Martelli, and A. Velardi, “Natural killer cell alloreactivity in allogeneic hematopoietic transplantation,” Current Opinion in Oncology, vol. 19, no. 2, pp. 142–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Cartron, L. Dacheux, G. Salles et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene,” Blood, vol. 99, no. 3, pp. 754–758, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. W. K. Weng and R. Levy, “Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3940–3947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Musolino, N. Naldi, B. Bortesi et al., “Immunoglobulin g fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1789–1796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Bibeau, E. Lopez-Crapez, F. D. Fiore et al., “Impact of fcγRIIa-fcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1122–1129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Zitvogel, A. Tesniere, and G. Kroemer, “Cancer despite immunosurveillance: immunoselection and immunosubversion,” Nature Reviews Immunology, vol. 6, no. 10, pp. 715–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Naito, K. Saito, K. Shiiba et al., “CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer,” Cancer Research, vol. 58, no. 16, pp. 3491–3494, 1998. View at Google Scholar · View at Scopus
  33. E. Sato, S. H. Olson, J. Ahn et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18538–18543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Gulubova, I. Manolova, D. Kyurkchiev, A. Julianov, and I. Altunkova, “Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases,” Acta Pathologica, Microbiologica et Immunologica, vol. 117, no. 12, pp. 870–879, 2009. View at Publisher · View at Google Scholar
  36. P. Carrega, B. Morandi, R. Costa et al., “Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16- cells and display an impaired capability to kill tumor cells,” Cancer, vol. 112, no. 4, pp. 863–875, 2008. View at Publisher · View at Google Scholar
  37. G. Sconocchia, G. C. Spagnoli, D. Del Principe et al., “Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves β-integrin-mediated interaction,” Neoplasia, vol. 11, no. 7, pp. 662–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Carlsten, H. Norell, Y. T. Bryceson et al., “Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells,” Journal of Immunology, vol. 183, no. 8, pp. 4921–4930, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Katou, H. Ohtani, Y. Watanabe, T. Nakayama, O. Yoshie, and K. Hashimoto, “Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer,” Cancer Research, vol. 67, no. 23, pp. 11195–11201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Baessler, J. E. Charton, B. J. Schmiedel et al., “CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells,” Blood, vol. 115, no. 15, pp. 3058–3069, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Konjević, K. Miräjaić Martinovi, V. Jurišić, N. Babović, and I. Spužić, “Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells,” Biomarkers, vol. 14, no. 4, pp. 258–270, 2009. View at Publisher · View at Google Scholar
  42. G. Markel, R. Seidman, M. J. Besser et al., “Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells,” PLoS ONE, vol. 4, no. 5, Article ID e5597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. J. Szczepanski, M. Szajnik, A. Welsh, K. A. Foon, T. L. Whiteside, and M. Boyiadzis, “Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors,” Cancer Immunology, Immunotherapy, vol. 59, no. 1, pp. 73–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. M. B. Fuertes, M. V. Girart, L. L. Molinero et al., “Intracellular retention of the NKG2D ligand MHC class i chain-related gene a in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity,” Journal of Immunology, vol. 180, no. 7, pp. 4606–4614, 2008. View at Google Scholar · View at Scopus
  45. P. J. Leibson, “Signal transduction during natural killer cell activation: inside the mind of a killer,” Immunity, vol. 6, no. 6, pp. 655–661, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Terunuma, X. Deng, Z. Dewan, S. Fujimoto, and N. Yamamoto, “Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections,” International Reviews of Immunology, vol. 27, no. 3, pp. 93–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Anfossi, P. André, S. Guia et al., “Human NK cell education by inhibitory receptors for MHC class I,” Immunity, vol. 25, no. 2, pp. 331–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. H. M. Horton, M. J. Bernett, E. Pong et al., “Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia,” Cancer Research, vol. 68, no. 19, pp. 8049–8057, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Zalevsky, I. W. L. Leung, S. Karki et al., “The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates,” Blood, vol. 113, no. 16, pp. 3735–3743, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. E. M. Levy, G. Sycz, J. M. Arriaga et al., “Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells,” Innate Immunity, vol. 15, no. 2, pp. 91–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Correale, M. Marra, C. Remondo et al., “Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC),” European Journal of Cancer, vol. 46, no. 9, pp. 1703–1711, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Pagès, A. Kirilovsky, B. Mlecnik et al., “In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5944–5951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Wulff, R. Pries, K. Börngen, T. Trenkle, and B. Wollenberg, “Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages,” Anticancer Research, vol. 29, no. 8, pp. 3053–3057, 2009. View at Google Scholar · View at Scopus
  55. M. Watanabe, K. Kono, Y. Kawaguchi et al., “Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma,” British Journal of Cancer, vol. 102, no. 3, pp. 520–529, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. H. I. Hurwitz, J. Yi, W. Ince, W. F. Novotny, and O. Rosen, “The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase in study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer,” Oncologist, vol. 14, no. 1, pp. 22–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Wu, M. Adams, T. Carter et al., “Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells,” Clinical Cancer Research, vol. 14, no. 14, pp. 4650–4657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Wu, A. Parton, L. Lu, M. Adams, P. Schafer, and J. B. Bartlett, “Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers,” Cancer Immunology, Immunotherapy, vol. 60, no. 1, pp. 61–73, 2011. View at Google Scholar
  59. D. Keizman, M. Zahurak, V. Sinibaldi et al., “Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study,” Clinical Cancer Research, vol. 16, no. 21, pp. 5269–5276, 2010. View at Publisher · View at Google Scholar
  60. Y. Kawaguchi, K. Kono, K. Mimura, H. Sugai, H. Akaike, and H. Fujii, “Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma,” International Journal of Cancer, vol. 120, no. 4, pp. 781–787, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Watanabe, K. Kono, Y. Kawaguchi et al., “NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma,” Diseases of the Esophagus, vol. 23, no. 8, pp. 675–681, 2010. View at Publisher · View at Google Scholar
  62. J. M. Roda, T. Joshi, J. P. Butchar et al., “The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor—positive tumor cells is enhanced by cytokines,” Clinical Cancer Research, vol. 13, no. 21, pp. 6419–6428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Kurai, H. Chikumi, K. Hashimoto et al., “Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines,” Clinical Cancer Research, vol. 13, no. 5, pp. 1552–1561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Hara, H. Nakanishi, K. Tsujimura et al., “Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity,” Cancer Science, vol. 99, no. 7, pp. 1471–1478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Kono, A. Takahashi, F. Ichihara, H. Sugai, H. Fujii, and Y. Matsumoto, “Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer,” Cancer Research, vol. 62, no. 20, pp. 5813–5817, 2002. View at Google Scholar · View at Scopus
  66. M. P. Roberti, M. M. Barrio, A. I. Bravo et al., “IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR,” Breast Cancer Research and Treatment. In press. View at Publisher · View at Google Scholar
  67. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. D. H. McKenna, D. Sumstad, N. Bostrom et al., “Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience,” Transfusion, vol. 47, no. 3, pp. 520–528, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Spanholtz, M. Tordoir, D. Eissens et al., “High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy,” PLoS ONE, vol. 5, no. 2, Article ID e9221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Sutlu, B. Stellan, M. Gilljam et al., “Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor,” Cytotherapy, vol. 12, no. 8, pp. 1044–1055, 2010. View at Publisher · View at Google Scholar
  71. D. H. Raulet and W. Held, “Natural killer cell receptors: the offs and ons of NK cell recognition,” Cell, vol. 82, no. 5, pp. 697–700, 1995. View at Google Scholar · View at Scopus
  72. K. Karre, “Express yourself or die: peptides, MHC molecules, and NK cells,” Science, vol. 267, no. 5200, pp. 978–979, 1995. View at Google Scholar · View at Scopus
  73. A. Moretta, M. Vitale, C. Bottino et al., “P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities,” Journal of Experimental Medicine, vol. 178, no. 2, pp. 597–604, 1993. View at Google Scholar · View at Scopus
  74. L. Ruggeri, M. Capanni, E. Urbani et al., “Effectiveness of donor natural killer cell aloreactivity in mismatched hematopoietic transplants,” Science, vol. 295, no. 5562, pp. 2097–2100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. K. C. Hsu and B. O. Dupont, “Natural killer cell receptors: regulating innate immune responses to hematologic malignancy,” Seminars in Hematology, vol. 42, no. 2, pp. 91–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Ruggeri, M. Capanni, A. Mancusi, M. F. Martelli, and A. Velardi, “The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation,” Transplant Immunology, vol. 14, no. 3-4, pp. 203–206, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Pfeiffer, M. Schumm, T. Feuchtinger, K. Dietz, R. Handgretinger, and P. Lang, “Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia,” British Journal of Haematology, vol. 138, no. 1, pp. 97–100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Yu, G. Heller, J. Chewning, S. Kim, W. M. Yokoyama, and K. C. Hsu, “Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands,” Journal of Immunology, vol. 179, no. 9, pp. 5977–5989, 2007. View at Google Scholar · View at Scopus
  79. S. Giebel, F. Locatelli, T. Lamparelli et al., “Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors,” Blood, vol. 102, no. 3, pp. 814–819, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Ruggeri, A. Mancusi, K. Perruccio, E. Burchielli, M. F. Martelli, and A. Velardi, “Natural killer cell alloreactivity for leukemia therapy,” Journal of Immunotherapy, vol. 28, no. 3, pp. 175–182, 2005. View at Google Scholar · View at Scopus
  81. D. W. Beelen, H. D. Ottinger, S. Ferencik et al., “Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias,” Blood, vol. 105, no. 6, pp. 2594–2600, 2005. View at Publisher · View at Google Scholar
  82. T. Kawase, K. Matsuo, K. Kashiwase et al., “HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism,” Blood, vol. 113, no. 12, pp. 2851–2858, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Cho, D. R. Shook, N. Shimasaki, Y.-H. Chang, H. Fujisaki, and D. Campana, “Cytotoxicity of activated natural killer cells against pediatric solid tumors,” Clinical Cancer Research, vol. 16, no. 15, pp. 3901–3909, 2010. View at Publisher · View at Google Scholar
  84. S. Arai, R. Meagher, M. Swearingen et al., “Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial,” Cytotherapy, vol. 10, no. 6, pp. 625–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. E. G. Iliopoulou, P. Kountourakis, M. V. Karamouzis et al., “A phase i trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 12, pp. 1781–1789, 2010. View at Publisher · View at Google Scholar
  86. M. A. Geller, S. Cooley, P. L. Judson et al., “A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer,” Cytotherapy, vol. 13, no. 1, pp. 98–107, 2010. View at Publisher · View at Google Scholar
  87. L. Barkholt, E. Alici, R. Conrad et al., “Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study,” Immunotherapy, vol. 1, no. 5, pp. 753–764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. V. Decot, L. Voillard, V. Latger-Cannard et al., “Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression,” Experimental Hematology, vol. 38, no. 5, pp. 351–362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Z. Jiang, A. J. Barrett, J. M. Goldman, and D. A. Mavroudis, “Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation,” Annals of Hematology, vol. 74, no. 1, pp. 1–6, 1997. View at Publisher · View at Google Scholar · View at Scopus